CY1123158T1 - Θεραπειες γονιδιακης ενισχυσης για την κληρονομικη εκφυλιση του αμφιβληστροειδους που προκαλειται απο μεταλλαξεις στο γονιδιο prpf31 - Google Patents
Θεραπειες γονιδιακης ενισχυσης για την κληρονομικη εκφυλιση του αμφιβληστροειδους που προκαλειται απο μεταλλαξεις στο γονιδιο prpf31Info
- Publication number
- CY1123158T1 CY1123158T1 CY20201100718T CY201100718T CY1123158T1 CY 1123158 T1 CY1123158 T1 CY 1123158T1 CY 20201100718 T CY20201100718 T CY 20201100718T CY 201100718 T CY201100718 T CY 201100718T CY 1123158 T1 CY1123158 T1 CY 1123158T1
- Authority
- CY
- Cyprus
- Prior art keywords
- gene
- mutations
- prpf31
- amphiblistroids
- therapies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Ophthalmology & Optometry (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562129638P | 2015-03-06 | 2015-03-06 | |
US201562147307P | 2015-04-14 | 2015-04-14 | |
PCT/US2016/021226 WO2016144892A1 (en) | 2015-03-06 | 2016-03-07 | Gene augmentation therapies for inherited retinal degeneration caused by mutations in the prpf31 gene |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1123158T1 true CY1123158T1 (el) | 2021-10-29 |
Family
ID=56879585
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20201100718T CY1123158T1 (el) | 2015-03-06 | 2020-08-04 | Θεραπειες γονιδιακης ενισχυσης για την κληρονομικη εκφυλιση του αμφιβληστροειδους που προκαλειται απο μεταλλαξεις στο γονιδιο prpf31 |
Country Status (15)
Country | Link |
---|---|
US (2) | US20180043034A1 (ja) |
EP (2) | EP3265568B1 (ja) |
JP (3) | JP6812368B2 (ja) |
CY (1) | CY1123158T1 (ja) |
DK (1) | DK3265568T3 (ja) |
ES (1) | ES2806054T3 (ja) |
HK (1) | HK1247637A1 (ja) |
HR (1) | HRP20201225T1 (ja) |
HU (1) | HUE051491T2 (ja) |
LT (1) | LT3265568T (ja) |
PL (1) | PL3265568T3 (ja) |
PT (1) | PT3265568T (ja) |
RS (1) | RS60668B1 (ja) |
SI (1) | SI3265568T1 (ja) |
WO (1) | WO2016144892A1 (ja) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8663624B2 (en) | 2010-10-06 | 2014-03-04 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
SG10201800873WA (en) | 2011-04-22 | 2018-03-28 | Univ California | Adeno-associated virus virions with variant capsid and methods of use thereof |
JP6600624B2 (ja) | 2013-05-31 | 2019-10-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | アデノ随伴ウイルス変異体及びその使用方法 |
EP3119798B1 (en) | 2014-03-17 | 2020-08-05 | Adverum Biotechnologies, Inc. | Compositions and methods for enhanced gene expression in cone cells |
WO2016141078A1 (en) | 2015-03-02 | 2016-09-09 | Avalanche Biotechnologies, Inc. | Compositions and methods for intravitreal delivery of polynucleotides to retinal cones |
LT3265568T (lt) * | 2015-03-06 | 2020-08-25 | Massachusetts Eye & Ear Infirmary | Genų augmentacijos terapijos, skirtos paveldimai tinklainės degeneracijai, sukeltai prpf31 geno mutacijos |
US10883117B2 (en) | 2015-03-24 | 2021-01-05 | The Regents Of The University Of California | Adeno-associated virus variants and methods of use thereof |
EP3827812A1 (en) | 2016-07-29 | 2021-06-02 | The Regents of the University of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
US20190185864A1 (en) | 2016-08-23 | 2019-06-20 | Akouos, Inc. | Compositions and methods for treating non-age-associated hearing impairment in a human subject |
US11192925B2 (en) | 2016-10-19 | 2021-12-07 | Adverum Biotechnologies, Inc. | Modified AAV capsids and uses thereof |
WO2018209154A1 (en) * | 2017-05-10 | 2018-11-15 | Massachusetts Eye And Ear Infirmary | Methods and compositions for modifying assembly-activating protein (app)-dependence of viruses |
CN110709511A (zh) | 2017-08-28 | 2020-01-17 | 加利福尼亚大学董事会 | 腺相关病毒衣壳变体及其使用方法 |
JP2021525531A (ja) * | 2018-06-01 | 2021-09-27 | ユニバーシティー オブ フロリダ リサーチ ファンデーション, インク. | 優性網膜色素変性症の処置のための組成物および方法 |
WO2020102740A2 (en) * | 2018-11-16 | 2020-05-22 | Spark Therapeutics, Inc. | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
EP4114958A1 (en) | 2020-02-21 | 2023-01-11 | Akouos, Inc. | Compositions and methods for treating non-age-associated hearing impairment in a human subject |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3023787A1 (de) | 1980-06-25 | 1982-01-21 | Studiengesellschaft Kohle mbH, 4330 Mülheim | Verfahren zur erhoehung der inkorporation und der expression von genetischem material in die kerne von intakten zellen mit hilfe von liposomen |
ATE68013T1 (de) | 1985-07-05 | 1991-10-15 | Whitehead Biomedical Inst | Expression von fremdem genetischem material in epithelzellen. |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
DE3852823T2 (de) | 1987-09-11 | 1995-05-24 | Whitehead Biomedical Inst | Transduktionsveränderte fibroblasten und ihre anwendung. |
JP2914692B2 (ja) | 1987-12-11 | 1999-07-05 | ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ | 内皮細胞の遺伝子修飾 |
JP2917998B2 (ja) | 1988-02-05 | 1999-07-12 | ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ | 修飾された肝細胞およびその用途 |
WO1991006309A1 (en) | 1989-11-03 | 1991-05-16 | Vanderbilt University | Method of in vivo delivery of functioning foreign genes |
AU656544B2 (en) | 1990-10-31 | 1995-02-09 | Brigham And Women's Hospital | Genetic modification of endothelial cells |
ES2150832B1 (es) | 1996-06-12 | 2001-06-16 | Fichtel & Sachs Ag | Dispositivo de maniobra para la maniobra, en particular maniobra neumatica, de un embrague de friccion. |
US6569662B1 (en) * | 2000-01-21 | 2003-05-27 | Hyseq, Inc. | Nucleic acids and polypeptides |
WO2002082904A2 (en) * | 2001-04-13 | 2002-10-24 | The Trustees Of The University Of Pennsylvania | Method of treating or retarding the development of blindness |
US20040208847A1 (en) * | 2003-03-28 | 2004-10-21 | Fabienne Rolling | Method and vectors for selectively transducing retinal pigment epithelium cells |
EP1991701A4 (en) * | 2006-02-14 | 2010-03-17 | Dana Farber Cancer Inst Inc | COMPOSITIONS, KITS, AND METHODS FOR IDENTIFYING, EVALUATING, PREVENTING, AND TREATING CANCER |
ES2907452T3 (es) * | 2007-04-12 | 2022-04-25 | The Provost Fellows Found Scholars & The Other Members Of Board Of The College Of The Holy & Undiv T | Supresión y reemplazo genético |
WO2008137066A1 (en) * | 2007-05-02 | 2008-11-13 | The Board Of Regents Of The University Of Oklahoma | Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases |
WO2009134681A2 (en) * | 2008-04-30 | 2009-11-05 | The Trustees Of The University Of Pennsylvania | Aav7 viral vectors for targeted delivery of rpe cells |
CA2729605A1 (en) * | 2008-06-30 | 2010-01-14 | The Johns Hopkins University | Compositions and methods for the treatment of ocular oxidative stress and retinitis pigmentosa |
GB201103062D0 (en) * | 2011-02-22 | 2011-04-06 | Isis Innovation | Method |
TWI702955B (zh) * | 2012-05-15 | 2020-09-01 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
AU2013287281B2 (en) * | 2012-07-11 | 2018-04-26 | The Trustees Of The University Of Pennsylvania | AAV-mediated gene therapy for RPGR x-linked retinal degeneration |
CN115093464A (zh) | 2013-10-11 | 2022-09-23 | 马萨诸塞眼科耳科诊所 | 预测祖先病毒序列的方法及其用途 |
EP3154573A1 (en) * | 2014-06-13 | 2017-04-19 | Universidade De Santiago De Compostela | Nanoparticulate systems for use in gene transfer or gene delivery |
LT3265568T (lt) | 2015-03-06 | 2020-08-25 | Massachusetts Eye & Ear Infirmary | Genų augmentacijos terapijos, skirtos paveldimai tinklainės degeneracijai, sukeltai prpf31 geno mutacijos |
-
2016
- 2016-03-07 LT LTEP16762307.3T patent/LT3265568T/lt unknown
- 2016-03-07 RS RS20200945A patent/RS60668B1/sr unknown
- 2016-03-07 PT PT167623073T patent/PT3265568T/pt unknown
- 2016-03-07 HU HUE16762307A patent/HUE051491T2/hu unknown
- 2016-03-07 WO PCT/US2016/021226 patent/WO2016144892A1/en active Application Filing
- 2016-03-07 JP JP2017564778A patent/JP6812368B2/ja active Active
- 2016-03-07 US US15/555,915 patent/US20180043034A1/en not_active Abandoned
- 2016-03-07 DK DK16762307.3T patent/DK3265568T3/da active
- 2016-03-07 EP EP16762307.3A patent/EP3265568B1/en active Active
- 2016-03-07 ES ES16762307T patent/ES2806054T3/es active Active
- 2016-03-07 EP EP20171646.1A patent/EP3748007A1/en active Pending
- 2016-03-07 PL PL16762307T patent/PL3265568T3/pl unknown
- 2016-03-07 SI SI201630873T patent/SI3265568T1/sl unknown
-
2018
- 2018-05-25 HK HK18106900.6A patent/HK1247637A1/zh unknown
-
2020
- 2020-08-04 CY CY20201100718T patent/CY1123158T1/el unknown
- 2020-08-04 HR HRP20201225TT patent/HRP20201225T1/hr unknown
- 2020-08-13 US US16/992,689 patent/US20210069347A1/en active Pending
- 2020-12-16 JP JP2020208068A patent/JP7239550B2/ja active Active
-
2023
- 2023-03-02 JP JP2023031931A patent/JP2023071867A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
LT3265568T (lt) | 2020-08-25 |
PL3265568T3 (pl) | 2020-11-30 |
JP2023071867A (ja) | 2023-05-23 |
EP3265568A4 (en) | 2018-08-08 |
US20210069347A1 (en) | 2021-03-11 |
HRP20201225T1 (hr) | 2020-11-13 |
US20180043034A1 (en) | 2018-02-15 |
EP3265568B1 (en) | 2020-05-06 |
JP2021059561A (ja) | 2021-04-15 |
JP6812368B2 (ja) | 2021-01-13 |
HK1247637A1 (zh) | 2018-09-28 |
WO2016144892A1 (en) | 2016-09-15 |
EP3265568A1 (en) | 2018-01-10 |
SI3265568T1 (sl) | 2020-10-30 |
JP2018511652A (ja) | 2018-04-26 |
JP7239550B2 (ja) | 2023-03-14 |
PT3265568T (pt) | 2020-08-20 |
EP3748007A1 (en) | 2020-12-09 |
RS60668B1 (sr) | 2020-09-30 |
HUE051491T2 (hu) | 2021-03-01 |
DK3265568T3 (da) | 2020-08-10 |
ES2806054T3 (es) | 2021-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1123158T1 (el) | Θεραπειες γονιδιακης ενισχυσης για την κληρονομικη εκφυλιση του αμφιβληστροειδους που προκαλειται απο μεταλλαξεις στο γονιδιο prpf31 | |
CY1123845T1 (el) | Τοπικα φαρμακευτικα σκευασματα για την αγωγη φλεγμονωδων καταστασεων | |
CY1120437T1 (el) | Νεα ινδαζολοκαρβοξαμιδια, μεθοδοι για την παραγωγη τους, φαρμακευτικα παρασκευασματα που τα περιεχουν, καθως και η χρηση αυτων για την παραγωγη φαρμακων | |
CY1122344T1 (el) | Blautia stercosis και wexlerae για χρηση στην θεραπευτικη αγωγη φλεγμονωδων και αυτοανοσων νοσων | |
CY1124663T1 (el) | Αντιιικα παραγωγα ν4-υδροξυκυτιδινης | |
PH12019502724A1 (en) | Compositions for modulating c9orf72 expression | |
CY1122631T1 (el) | Παραγωγα χολανης για χρηση στη θεραπευτικη αγωγη ή/και προληψη fxr και μεσολαβουμενων απο τgr5/gρβαr1 ασθενειων | |
CY1125364T1 (el) | Συνθεσεις και μεθοδοι για την αναστολη της εκφρασης του γονιδιου ηαο1 (οξειδαση υδροξυοξεος 1 (γλυκολικη οξειδαση) | |
CY1122184T1 (el) | Συνθεσεις περιλαμβανουσες βακτηριακα στελεχη | |
CY1123354T1 (el) | Συνθεσεις τοπικης εφαρμογης που περιλαμβανουν ενα κορτικοστεροειδες και ενα ρετινοειδες για τη θεραπεια της ψωριασης | |
MD3209310T2 (ro) | Compoziții care conțin tulpini bacteriene | |
PH12017500614A1 (en) | Compositions and methods for silencing hepatitis b virus gene expression | |
MX2021013638A (es) | Composiciones farmaceuticas para el tratamiento de enfermedades mediadas por el regulador de conductancia de transmembrana de fibrosis quistica. | |
CY1119419T1 (el) | C1-inh συνθεσεις για χρηση στην προληψη και αγωγη κληρονομικου αγγειοοιδηματος (ηαε) | |
EP4219532A3 (en) | Compositions and methods for transient gene therapy with enhanced stability | |
EA201791243A1 (ru) | Лечение пузырчатки | |
MX2018009750A (es) | Composiciones potenciadoras de vcn y métodos para su uso. | |
MX2015008889A (es) | Metodo para tratar cancer con base en el estado de la mutacion k-ras. | |
CY1123963T1 (el) | Καινοτομα πολυμερικα προφαρμακα hgh | |
MX2023008211A (es) | Composiciones y metodos para disminuir la expresion de tau. | |
MX2019002699A (es) | Terapia genica para pacientes con anemia de fanconi. | |
BR112018070497A2 (pt) | métodos e formulações farmacêuticas para tratamento de condições oculares | |
CY1125014T1 (el) | Υποκατεστημενα παραγωγα ξανθινης | |
EP3344641A4 (en) | AMINO-LIKES DERIVATIVES AND USES THEREOF FOR THE TREATMENT OF GENETIC DISEASES | |
MX2016015568A (es) | Derivados de nucleosidos para el tratamiento del cancer. |